Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625620 | 0.89 | PIK3CA (0.56) | PIK3CAKCNH2 | |
| SCHEMBL625746 | 0.89 | PIK3CA (0.54) | PIK3CAKCNH2 | |
| SCHEMBL627410 | 0.88 | PIK3CA (0.57) | PIK3CAKCNH2 | |
| SCHEMBL624411 | 0.85 | PIK3CA (0.54) | PIK3CAKCNH2 | |
| SCHEMBL626464 | 0.85 | MAPT (0.47) | PIK3CALMNAL3MBTL1 | |
| SCHEMBL627372 | 0.85 | PIK3CA (0.57) | PIK3CAKCNH2 | |
| SCHEMBL625227 | 0.84 | PIK3CA (0.55) | PIK3CAKCNH2 | |
| SCHEMBL625222 | 0.83 | PIK3CA (0.48) | PIK3CAPIK3CDPIK3CBPIK3CGKCNH2 | |
| SCHEMBL624388 | 0.83 | PIK3CA (0.55) | PIK3CAKCNH2 | |
| SCHEMBL624967 | 0.83 | PIK3CA (0.55) | PIK3CAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012020215-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |